Key result
Direct sequencing of ITGA2B and ITGB3 genes identified causative mutations in 87.5% of Iranian patients with Glanzmann thrombasthenia, revealing 14 novel mutations with no recurrent mutations.
Why the study?
Glanzmann thrombasthenia is more prevalent in populations with higher rates of consanguineous marriages, such as in Iran, and is caused by mutations in ITGA2B and ITGB3 genes.
Observational (n=16)
The study identified 14 novel mutations in the ITGA2B and ITGB3 genes among Iranian patients with Glanzmann thrombasthenia, highlighting significant genetic heterogeneity and a lack of recurrent mutations in this population.
May aid targeted GT diagnosis in Iranians; leaves open functional validation and broader applicability.
BACKGROUND: Glanzmann thrombasthenia (GT) is a rare autosomal recessive abnormality of platelet aggregation with quantitative and/or qualitative abnormality of αIIbβ3 integrin. The αIIbβ3 is a platelet fibrinogen receptor, which is required for platelet aggregation, firm adhesion, and also spreading. The disease is more prevalent in the populations with a higher rate of consanguineous marriages as in some Middle Eastern populations including Iraq, Jordan, and Iran. Different types of mutations in ITGA2B and ITGB3 genes have been previously reported to cause the disease. RESULT: In this study, 16 patients with the clinical diagnosis of GT were studied. Direct sequencing of the exons and exon-intron boundaries of the above genes revealed mutations in 14 patients (detection rate: 87.5%). Briefly, out of fifteen types of identified mutations, 14 were novel. Seven mutations in the ITGB3 gene included 4 missense [c.2T > C, c.155 G > T, c. 538 G > A, c.1990 G > T], one nonsense mutation [c.1303 G > T], a small deletion [c.1656_1658delCTC] and a deletion of one nucleotide [c.401delA]. Mutations in the ITGA2B were 8 different mutations consisting 2 missense [c.286 T > A, c.842 C > T], 2 deletions [c.1899 del T, c.189-319_236del], an insertion [c.1071_1072insG] and one splice site mutations [c.409-3 C > G], one synonymous mutation that might alter the normal splicing process [c.1392 A > G] and a nonsense mutation [c.1555 C > T]. The causative mutation in 2 patients remained unknown. Using long-range PCR and sequencing, we found a rather large deletion. The break point of this deletion covers 319 nt from the last part of the first intron and 48 nt from the beginning of the second exon of ITGA2B gene. The deletion was also detected in two unrelated patients with the same ethnicity. In addition, in silico analyses of novel mutations were performed. CONCLUSION: There was no recurrent mutation in the studied population. This may be due to either small sample size or the heterogeneity of the studied population.
No takes yet. Share an insight, caveat, or question.
Motlagh et al. (2019) conducted an observational in Glanzmann thrombasthenia (n=16). Molecular genetic testing of ITGA2B and ITGB3 genes was evaluated on Detection of causative mutations in ITGA2B and ITGB3 genes. Direct sequencing of ITGA2B and ITGB3 genes identified causative mutations in 87.5% of Iranian patients with Glanzmann thrombasthenia, revealing 14 novel mutations with no recurrent mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: